Developing a Low-Intensity Primary Care Intervention for Anxiety Disorders (AIM-PC)
| Status: | Recruiting |
|---|---|
| Conditions: | Anxiety |
| Therapuetic Areas: | Psychiatry / Psychology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 1/20/2018 |
| Start Date: | September 2015 |
| End Date: | December 2018 |
| Contact: | Risa B Weisberg, PhD |
| Email: | risa_weisberg@brown.edu |
| Phone: | 774-826-2825 |
Phase 2 Randomized Controlled Trial of Attention and Interpretation Modification (AIM) for Anxiety Disorders in Primary Care
The purpose of the study is to develop a personalized, user-friendly computerized treatment
for anxiety disorders linked to primary care. The computerized treatment is a type of
Cognitive Bias Modification, which targets attention and interpretation biases known to
maintain anxiety disorders.
for anxiety disorders linked to primary care. The computerized treatment is a type of
Cognitive Bias Modification, which targets attention and interpretation biases known to
maintain anxiety disorders.
The primary goals of our 3-year, 2-phase project are to develop AIM for primary care linkage
and assess its feasibility and acceptability. This protocol description only pertains to
Phase 2 (Randomized Controlled Trial).
42 primary care patients with primary Generalized Anxiety Disorder, Social Anxiety Disorder,
and/or Panic Disorder (with or without Agoraphobia) will be randomly assigned to the AIM
treatment or to a symptom tracking control group. Full assessments will occur pre- and
post-treatment and 3-months follow-up. A mid-treatment assessment will include measures of
cognitive biases and the primary outcome. Weekly measures of anxiety and depression will be
collected, as will feedback from patients and PCPs about the research and delivery
procedures.
and assess its feasibility and acceptability. This protocol description only pertains to
Phase 2 (Randomized Controlled Trial).
42 primary care patients with primary Generalized Anxiety Disorder, Social Anxiety Disorder,
and/or Panic Disorder (with or without Agoraphobia) will be randomly assigned to the AIM
treatment or to a symptom tracking control group. Full assessments will occur pre- and
post-treatment and 3-months follow-up. A mid-treatment assessment will include measures of
cognitive biases and the primary outcome. Weekly measures of anxiety and depression will be
collected, as will feedback from patients and PCPs about the research and delivery
procedures.
Inclusion Criteria:
Study site patient Age ≥18 Primary diagnosis of Generalized anxiety disorder (GAD), Social
Phobia (SP), and/or panic disorder with or without agoraphobia (PD/A) At least moderate
anxiety severity (GAD-7 score > 10) English-speaking If on psychopharmacotherapy, stable
dose for 3 months; to minimize learning effects, patients taking benzodiazepines will
complete AIM prior to their first dose of the day No current psychotherapy No current
severe psychiatric symptoms requiring immediate attention (e.g., imminent suicidality,
psychosis)
We found this trial at
1
site
Pawtucket, Rhode Island 02860
Phone: 401-444-1964
Click here to add this to my saved trials
